Tatsuya Deguchi

Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 20 publications

Survival of dogs with melanoma from a referral veterinary hospital in Japan.

Survival of dogs with melanoma from a referral veterinary hospital in Japan.

Journal: The Journal of veterinary medical science

Published: February 11, 2026

Clinical efficacy of anti-programmed death ligand 1 antibody HFC-L1/c4G12 in dogs with malignant tumors: an exploratory study.

Clinical efficacy of anti-programmed death ligand 1 antibody HFC-L1/c4G12 in dogs with malignant tumors: an exploratory study.

Journal: The Journal of veterinary medical science

Published: October 13, 2025

Glutathione-associated redox regulation alleviates radio-resistance of canine cancer stem-like cells with low proteasome activity.

Glutathione-associated redox regulation alleviates radio-resistance of canine cancer stem-like cells with low proteasome activity.

Journal: Scientific reports

Published: March 03, 2025

Outcomes and Prognostic Factors in Dogs With Presumed Intracranial Gliomas Treated With Definitive-Intent Intensity Modulated Radiation Therapy: 55 Cases (2014-2023).

Outcomes and Prognostic Factors in Dogs With Presumed Intracranial Gliomas Treated With Definitive-Intent Intensity Modulated Radiation Therapy: 55 Cases (2014-2023).

Journal: Veterinary and comparative oncology

Published: February 27, 2025

Development of caninized anti-CTLA-4 antibody as salvage combination therapy for anti-PD-L1 refractory tumors in dogs.

Development of caninized anti-CTLA-4 antibody as salvage combination therapy for anti-PD-L1 refractory tumors in dogs.

Journal: Frontiers in immunology

Published: February 04, 2025

Enhancement of radio-sensitivity by inhibition of Janus kinase signaling with oclacitinib in canine tumor cell lines.

Enhancement of radio-sensitivity by inhibition of Janus kinase signaling with oclacitinib in canine tumor cell lines.

Journal: Molecular therapy. Oncology

Published: November 06, 2024

Influence of the Hypoxia-Activated Prodrug Evofosfamide (TH-302) on Glycolytic Metabolism of Canine Glioma: A Potential Improvement in Cancer Metabolism.

Influence of the Hypoxia-Activated Prodrug Evofosfamide (TH-302) on Glycolytic Metabolism of Canine Glioma: A Potential Improvement in Cancer Metabolism.

Journal: Cancers

Published: September 18, 2023

Safety and clinical efficacy of an anti-PD-L1 antibody (c4G12) in dogs with advanced malignant tumours.

Safety and clinical efficacy of an anti-PD-L1 antibody (c4G12) in dogs with advanced malignant tumours.

Journal: PloS one

Published: July 20, 2023

Comparison of chemotherapy outcomes between normal and high serum cortisol concentration in dogs with lymphoma.

Comparison of chemotherapy outcomes between normal and high serum cortisol concentration in dogs with lymphoma.

Journal: Journal of veterinary internal medicine

Published: June 14, 2023

Enhanced Systemic Antitumour Immunity by Hypofractionated Radiotherapy and Anti-PD-L1 Therapy in Dogs with Pulmonary Metastatic Oral Malignant Melanoma.

Enhanced Systemic Antitumour Immunity by Hypofractionated Radiotherapy and Anti-PD-L1 Therapy in Dogs with Pulmonary Metastatic Oral Malignant Melanoma.

Journal: Cancers

Published: April 07, 2023

Molecular characterization of feline immune checkpoint molecules and establishment of PD-L1 immunohistochemistry for feline tumors.

Molecular characterization of feline immune checkpoint molecules and establishment of PD-L1 immunohistochemistry for feline tumors.

Journal: PloS one

Published: November 04, 2022

Regulation of programmed death ligand 1 expression by interferon-γ and tumour necrosis factor-α in canine tumour cell lines.

Regulation of programmed death ligand 1 expression by interferon-γ and tumour necrosis factor-α in canine tumour cell lines.

Journal: Veterinary and comparative oncology

Published: October 18, 2022

Showing 1-12 of 20

Last Updated: 09/26/2026